Morgan Stanley
BCLI

Morgan Stanley’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Morgan Stanley’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,803
Closed -$6.5K – 8175
2025
Q2 		$6.5K Buy
5,803
+1,465
+34% +$1.64K ﹤0.01% 6962
2025
Q1 		$5.47K Buy
4,338
+21
+0.5% +$37 ﹤0.01% 6968
2024
Q4 		$9.8K Buy
4,317
+1,019
+31% +$1.88K ﹤0.01% 6810
2024
Q3 		$11.4K Buy
3,298
+833
+34% +$3.93K ﹤0.01% 6680
2024
Q2 		$12.5K Sell
2,465
-208
-8% -$1.56K ﹤0.01% 6600
2024
Q1 		$22.6K Sell
2,673
-4,187
-61% -$23K ﹤0.01% 6452
2023
Q4 		$28.1K Buy
6,860
+4,823
+237% +$14.5K ﹤0.01% 6544
2023
Q3 		$6.12K Buy
2,037
+108
+6% +$2.46K ﹤0.01% 6869
2023
Q2 		$59.6K Sell
1,929
-660
-25% -$27.4K ﹤0.01% 6145
2023
Q1 		$128K Buy
2,589
+983
+61% +$28.5K ﹤0.01% 5913
2022
Q4 		$39.5K Sell
1,606
-828
-34% -$31K ﹤0.01% 6392
2022
Q3 		$162K Sell
2,434
-298
-11% -$14.9K ﹤0.01% 5826
2022
Q2 		$113K Sell
2,732
-542
-17% -$24.4K ﹤0.01% 6209
2022
Q1 		$164K Sell
3,274
-170
-5% -$8.35K ﹤0.01% 6026
2021
Q4 		$207K Sell
3,444
-57
-2% -$2.81K ﹤0.01% 6042
2021
Q3 		$174K Sell
3,501
-78
-2% -$4.1K ﹤0.01% 6072
2021
Q2 		$205K Buy
3,579
+1,064
+42% +$56.8K ﹤0.01% 6003
2021
Q1 		$145K Sell
2,515
-11,685
-82% -$882K ﹤0.01% 5830
2020
Q4 		$964K Buy
14,200
+7,023
+98% +$956K ﹤0.01% 4691
2020
Q3 		$1.82M Buy
7,177
+1,561
+28% +$320K ﹤0.01% 3738
2020
Q2 		$944K Buy
5,616
+3,894
+226% +$420K ﹤0.01% 4222
2020
Q1 		$120K Buy
1,722
+438
+34% +$34.2K ﹤0.01% 5106
2019
Q4 		$82K Buy
1,284
+70
+6% +$4.06K ﹤0.01% 5709
2019
Q3 		$71K Sell
1,214
-170
-12% -$10K ﹤0.01% 5567
2019
Q2 		$82K Buy
1,384
+51
+4% +$2.97K ﹤0.01% 5412
2019
Q1 		$87K Buy
1,333
+680
+104% +$38.7K ﹤0.01% 5450
2018
Q4 		$35K Hold
653
– – ﹤0.01% 5855
2018
Q3 		$37K Sell
653
-2,885
-82% -$174K ﹤0.01% 5959
2018
Q2 		$207K Buy
3,538
+258
+8% +$15.2K ﹤0.01% 5521
2018
Q1 		$155K Buy
3,280
+2,733
+500% +$138K ﹤0.01% 5569
2017
Q4 		$32K Buy
547
+147
+37% +$8.79K ﹤0.01% 5958
2017
Q3 		$25K Hold
400
– – ﹤0.01% 5971
2017
Q2 		$25K Hold
400
– – ﹤0.01% 6039
2017
Q1 		$26K Buy
400
+167
+72% +$8.69K ﹤0.01% 6005
2016
Q4 		$9K Buy
233
+166
+248% +$5.75K ﹤0.01% 6174
2016
Q3 		$2K Buy
+67
New +$2.51K ﹤0.01% 6359
2015
Q4 		– Sell
-7
Closed – – 6660
2015
Q3 		$0 Buy
+7
New +$329 ﹤0.01% 6607

Other funds holding BCLI

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BSB
Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return
VWA
VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Morgan Stanley's BCLI Position: Q3 2025 in Review

Morgan Stanley sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 5,803 shares — an estimated $6.5K sold.

Morgan Stanley first reported a position in BCLI in Q3 2015 and held it in 37 quarters. The position peaked at $1.82M in Q3 2020. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

  • Morgan Stanley reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
  • Morgan Stanley sold 5,803 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $6.5K.
  • Morgan Stanley first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2015 and held it in 37 quarters.
  • Morgan Stanley's BRAINSTORM CELL THERAPUTC position peaked at $1.82M in Q3 2020.
  • 5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Morgan Stanley's 13F filing for Q3 2025, filed 14 Nov 2025.